By Josh White
Date: Thursday 04 Sep 2025
(Sharecast News) - Oxford BioDynamics said on Thursday that interim results from its ongoing FDA-registered PROWES trial demonstrated that its EpiSwitch CiRT test had a significant impact on treatment decisions for cancer patients receiving immune checkpoint inhibitors.
By Josh White
Date: Wednesday 13 Aug 2025
(Sharecast News) - Oxford BioDynamics announced a collaboration with Google Cloud on Wednesday, to accelerate the development and deployment of its cloud-based analytical framework for precision medicine.
By Josh White
Date: Friday 09 May 2025
(Sharecast News) - Oxford BioDynamics announced on Friday that its Oxford-based laboratory had been accredited by the UK Accreditation Service (UKAS) as a clinical facility under ISO 15189, enabling it to process 'EpiSwitch' clinical tests in the UK.
| Currency | UK Pounds |
| Share Price | 0.32p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 2.20p |
| 52 Week Low | 0.26p |
| Volume | 37,609,827 |
| Shares Issued | 1,957.58m |
| Market Cap | £6.17m |
| Value | ![]() |
|---|
| Price Trend | ![]() |
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:12 | 4,500,000 @ 0.32p |
| 16:26 | 75,901 @ 0.32p |
| 16:23 | 1,236,828 @ 0.32p |
| 16:17 | 24,000 @ 0.32p |
| 16:16 | 500,000 @ 0.31p |
You are here: research